Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial

COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in no...

Full description

Saved in:

Bibliographic Details
Published in:	Circulation (New York, N.Y.) Vol. 147; no. 25; p. 1891
Main Authors:	Piazza, Gregory, Spyropoulos, Alex C, Hsia, Judith, Goldin, Mark, Towner, William J, Go, Alan S, Bull, Todd M, Weng, Stephen, Lipardi, Concetta, Barnathan, Elliot S, Bonaca, Marc P
Format:	Journal Article
Language:	English
Published:	United States 20.06.2023
Subjects:	Anticoagulants - adverse effects COVID-19 Hemorrhage - chemically induced Hemorrhage - drug therapy Hospitalization Humans Outpatients Rivaroxaban - adverse effects Thrombosis - epidemiology Thrombosis - prevention & control COVID-19 pre-exposure prophylaxis prevention and control rivaroxaban thrombosis venous thromboembolism
ISSN:	1524-4539, 1524-4539
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!